c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection

Vaccine

Volumn 26, Issue 36, 2008, Pages 4676-4685

  Ogunniyi, Abiodun D ^a   Paton, James C ^a   Kirby, Alun C ^b   McCullers, Jonathan A ^c   Cook, Jan ^a   Hyodo, Mamoru ^d   Hayakawa, Yoshihiro ^d   Karaolis, David K R ^e,f  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NAGOYA UNIVERSITY   (Japan)

^e Intragenics Research Institute   (United States)

^f Karagen Pharmaceuticals   (United States)

Author keywords

Adjuvant; c di GMP; Immunomodulator; Streptococcus pneumoniae; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL PROTEIN; CYCLIC DIGUANYLATE; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; MEMBRANE PROTEIN; PLACEBO; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; FEMALE; GROWTH RATE; INNATE IMMUNITY; LUNG; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BLOOD; COLONY COUNT, MICROBIAL; CYCLIC GMP; FEMALE; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; LUNG; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; SURVIVAL ANALYSIS;

EID: 48649084066     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.099     Document Type: Article

References (50)

1. CDC. Assessment of susceptibility testing practices for Streptococcus pneumoniae-United States, February 2000. MMWR 51 18 (2002) 392-394
2. Paton J.C. New pneumococcal vaccines: basic science developments. In: Tuomanen E.I., Mitchell T.J., Morrison D.A., and Spratt B.G. (Eds). The pneumococcus (2004), ASM Press, Washington, DC 382-402
3. Amikam D., and Benziman M. Cyclic diguanylic acid and cellulose synthesis in Agrobacterium tumefaciens. J Bacteriol 171 12 (1989) 6649-6655
4. Ross P., Mayer R., Weinhouse H., Amikam D., Huggirat Y., Benziman M., et al. The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J Biol Chem 265 31 (1990) 18933-18943
5. Ross P., Weinhouse H., Aloni Y., Michaeli D., Weinberger-Ohana P., Mayer R., et al. Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325 (1987) 279-281
6. D'Argenio D.A., and Miller S.I. Cyclic di-GMP as a bacterial second messenger. Microbiology 150 Part 8 (2004) 2497-2502
7. Galperin M.Y., Nikolskaya A.N., and Koonin E.V. Novel domains of the prokaryotic two-component signal transduction systems. FEMS Microbiol Lett 203 1 (2001) 11-21
8. Jones H.A., Lillard Jr. J.W., and Perry R.D. HmsT, a protein essential for expression of the haemin storage (Hms+) phenotype of Yersinia pestis. Microbiology 145 Part 8 (1999) 2117-2128
9. Rashid M.H., Rajanna C., Ali A., and Karaolis D.K.R. Identification of genes involved in the switch between the smooth and rugose phenotypes of Vibrio cholerae. FEMS Microbiol Lett 227 1 (2003) 113-119
10. Römling U., Gomelsky M., and Galperin M.Y. C-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 57 3 (2005) 629-639
11. Römling U., and Amikam D. Cyclic di-GMP as a second messenger. Curr Opin Microbiol 9 2 (2006) 218-228
12. D'Argenio D.A., Calfee M.W., Rainey P.B., and Pesci E.C. Autolysis and autoaggregation in Pseudomonas aeruginosa colony morphology mutants. J Bacteriol 184 23 (2002) 6481-6489
13. Hecht G.B., and Newton A. Identification of a novel response regulator required for the swarmer-to-stalked-cell transition in Caulobacter crescentus. J Bacteriol 177 21 (1995) 6223-6229
14. Karaolis D.K.R., Rashid M.H., Rajanna C., Luo W., Hyodo M., and Hayakawa Y. c-di-GMP (3′-5′-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 49 3 (2005) 1029-1038
15. Römling U., Rohde M., Olsen A., Normark S., and Reinkoster J. AgfD, the checkpoint of multicellular and aggregative behaviour in Salmonella typhimurium regulates at least two independent pathways. Mol Microbiol 36 1 (2000) 10-23
16. Brouillette E., Hyodo M., Hayakawa Y., Karaolis D.K.R., and Malouin F. 3′,5′-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob Agents Chemother 49 8 (2005) 3109-3113
17. Karaolis D.K.R., Means T.K., Yang D., Takahashi M., Yoshimura T., Muraille E., et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178 4 (2007) 2171-2181
18. Karaolis D.K.R., Cheng K., Lipsky M., Elnabawi A., Catalano J., Hyodo M., et al. 3′,5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun 329 1 (2005) 40-45
19. Karaolis D.K.R., Newstead M.W., Zeng X., Hyodo M., Hayakawa Y., Bhan U., et al. Cyclic-di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 75 10 (2007) 4942-4950
20. Avery O.T., MacLeod C.M., and McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79 2 (1944) 137-158
21. Tettelin H., Nelson K.E., Paulsen I.T., Eisen J.A., Read T.D., Peterson S., et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293 5529 (2001) 498-506
22. Francis K.P., Yu J., Bellinger-Kawahara C., Joh D., Hawkinson M.J., Xiao G., et al. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposing. Infect Immun 69 5 (2001) 3350-3358
23. Hyodo M., Hayakawa Y., and Karaolis D.K.R. Organic synthesis, chemical properties, and biological activities of cyclic bus(3′-5′) diguanylic acid (c-di-GMP) and its analogy. J Synch Org Chem Jon 64 4 (2006) 359-370
24. Bridles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182 6 (2000) 1694-1701
25. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18 17 (2000) 1743-1754
26. Ogunniyi A.D., Folland R.L., Bridles D.E., Hollingshead S.K., and Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68 5 (2000) 3028-3033
27. Paton J.C., Lock R.A., Lee C.J., Li J.P., Berry A.M., Mitchell T.J., et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 59 7 (1991) 2297-2304
28. Cognet I., de Coignac A.B., Magistrelli G., Jeannin P., Aubry J.P., Maisnier-Patin K., et al. Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods 272 1-2 (2003) 199-210
29. Ogunniyi A.D., Grabowicz M., Bridles D.E., Cook J., and Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75 1 (2007) 350-357
30. Weiser J.N., Austrian R., Sreenivasan P.K., and Masure H.R. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 62 6 (1994) 2582-2589
31. Kirby A.C., Raynes J.G., and Kaye P.M. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J Infect Dis 191 9 (2005) 1538-1547
32. Kirby A.C., Raynes J.G., and Kaye P.M. CD11b regulates recruitment of alveolar macrophages but not pulmonary dendritic cells after pneumococcal challenge. J Infect Dis 193 2 (2006) 205-213
33. Orihuela C.J., Gao G., McGee M., Yu J., Francis K.P., and Tuomanen E.I. Organ-specific models of Streptococcus pneumoniae disease. Scand J Infect Dis 35 9 (2003) 647-652
34. McDaniel L.S., Sheffield J.S., Delucchi P., and Bridles D.E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 59 1 (1991) 222-228
35. Broug-Holub E., Toews G.B., van Iwaarden J.F., Strieter R.M., Kunkel S.L., Paine R., et al. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 65 4 (1997) 1139-1146
36. Lipscomb M.F., Onofrio J.M., and Nash E.J. A morphological study of the role of phagocytes in the clearance of Staphylococcus aureus from the lung. J Reticuloend Soc 33 6 (1983) 429-442
37. Toews G.B., Gross G.N., and Pierce A.K. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 120 3 (1980) 559-566
38. Tsai W.C., Strieter R.M., Mehrad B., Newstead M.W., Zeng X., and Standiford T.J. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 68 7 (2000) 4289-4296
39. Deng J.C., Tateda K., Zeng X., and Standiford T.J. Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun 69 10 (2001) 6382-6390
40. Ferlazzo G., Morandi B., D'Agostino A., Meazza R., Melioli G., Moretta A., et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 33 2 (2003) 306-313
41. Gonzalez-Aseguinolaza G., de Oliveira C., Tomaska M., Hong S., Bruna-Romero O., Nakayama T., et al. Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 97 15 (2000) 8461-8466
42. Kawakami K., Kinjo Y., Yara S., Koguchi Y., Uezu K., Nakayama T., et al. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 69 1 (2001) 213-220
43. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21 (2003) 483-513
44. Kawakami K., Yamamoto N., Kinjo Y., Miyagi K., Nakasone C., Uezu K., et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 33 12 (2003) 3322-3330
45. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 13 (2005) 4848-4853
46. McCool T.L., and Weiser J.N. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun 72 10 (2004) 5807-5813
47. Kadioglu A., Gingles N.A., Grattan K., Kerr A., Mitchell T.J., and Andrew P.W. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 68 2 (2000) 492-501
48. Kadioglu A., Coward W., Colston M.J., Hewitt C.R., and Andrew P.W. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 72 5 (2004) 2689-2697
49. Zhang Q., Bagrade L., Bernatoniene J., Clarke E., Paton J.C., Mitchell T.J., et al. Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. J Infect Dis 195 8 (2007) 1194-1202
50. Baril L., Dietemann J., Essevaz-Roulet M., Béniguel L., Coan P., Bridles D.E., et al. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin Exp Immunol 145 2 (2006) 277-286